{"id":795569,"date":"2024-12-17T16:04:33","date_gmt":"2024-12-17T21:04:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\/"},"modified":"2024-12-17T16:04:33","modified_gmt":"2024-12-17T21:04:33","slug":"corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\/","title":{"rendered":"Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024"},"content":{"rendered":"<h2>\nCompany to host conference call and webcast at 8:00 a.m. ET \/ 5:00 a.m. PT on Wednesday, December 18, 2024<br \/>\n<\/h2>\n<div class=\"mw_release\">\n<p align=\"left\">BURLINGAME, Calif., Dec.  17, 2024  (GLOBE NEWSWIRE) &#8212; Corvus Pharmaceuticals, Inc.\u00a0(NASDAQ: CRVS), a clinical-stage biopharmaceutical company, will announce interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis tomorrow, December 18, 2024. The data will be provided in a press release and presented during a conference call and webcast.<\/p>\n<p align=\"left\">\n        <strong>Conference Call, Webcast and Presentation Slides <\/strong><br \/>\n        <br \/>Corvus will host a conference call and webcast tomorrow, Wednesday, December 18, 2024 at 8:00 a.m. ET \/ 5:00 a.m. PT to provide an overview of the soquelitinib atopic dermatitis Phase 1 clinical data. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hfSM_16x0ennjyHQytnsbXK8X-E2WoIFGumvZSXyCcbHFbY_KLBGuyzCHSezz0bO_p5Wftjy7iiTJujsfYs-Ow==\" rel=\"nofollow\" target=\"_blank\"><u>this link<\/u><\/a> for telephone access to the event. The live webcast, which will include presentation slides, may be accessed via the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KnBQW2QbjYusqj1v3Hi_X1x_suLWy_16WcOJJP7fSBVMsOwq2zl0MldIpX0VN31XKPL9cynPshgMFZFPY2G0Ee4b3QXK8FLqnnXvnOXuAK4=\" rel=\"nofollow\" target=\"_blank\"><u>investor relations<\/u><\/a> section of the Corvus website. A replay of the webcast will be available on Corvus\u2019 website for 60 days.<\/p>\n<p align=\"left\">\n        <strong>About Soquelitinib <\/strong><br \/>\n        <br \/>Soquelitinib (formerly CPI-818) is an investigational small molecule drug given orally designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase), an enzyme that is expressed predominantly in T cells and plays a role in T cell and natural killer (NK) cell immune function. Soquelitinib has been shown to affect T cell differentiation and induce the generation of Th1 helper cells while blocking the development of both Th2 and Th17 cells and production of their secreted cytokines. Th1 T cells are required for immunity to tumors, viral infections and other infectious diseases. Th2 and Th17 helper T cells are involved in the pathogenesis of many autoimmune and allergic diseases. The Company believes the inhibition of specific molecular targets in T cells may be of therapeutic benefit for patients with cancers, including solid tumors, and in patients with autoimmune and allergic diseases. Recent studies have demonstrated that ITK controls a switch between the differentiation of Th17 proinflammatory cells and T regulatory suppressor cells. Inhibition of ITK leads to a shift toward T regulatory cell differentiation which has the potential to suppress autoimmune and inflammatory reactions. Based on interim results from a Phase 1\/1b clinical trial in patients with refractory T cell lymphomas, which demonstrated tumor responses in very advanced, refractory, difficult to treat T cell malignancies, the Company has initiated a registrational Phase 3 clinical trial (<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VJzc3zhRtU8H-dxUgfMlD7918is78KJTat71LVIA5OtzYM7ebHp_8eRIh2JVt_1CEwJkT5tRG6Ssdj9F98x9VhOt5MWbw6u6wH_ZyXktcerfMAFLmRHcudvyRnixyZre-xCt7y15mutGOZKSZoZrng==\" rel=\"nofollow\" target=\"_blank\"><u>NCT06561048<\/u><\/a>) of soquelitinib in patients with relapsed peripheral T cell lymphoma. Soquelitinib is also now being investigated in a randomized placebo-controlled phase 1 clinical trial in patients with atopic dermatitis. A recent publication describing the chemistry, enzymology and biology of soquelitinib appeared in npj Drug Discovery in December 2024 and is available online at the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=eFSVbQzoa1brUBZ28ftyuV92Oavc8GVtMBKXAq_5vKHNAfdVIOXoCeI5c8ISOB_yZVGNPrfQsW4s_CQlo4YX6qHSmlmkcY9OH_wjJI3922o=\" rel=\"nofollow\" target=\"_blank\"><u>Nature<\/u><\/a> website and on the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=voXqO3mg0LNIs_HWIltdiRbIKJrv557SIQmbFUbsQrf-4bckgG2RhjLQTazAxE7qbbeszTRPp8b_596VF-Jo3cSxYgAGFGOkKwqK30UbFHC6kpNavieTtpzCQKydvBNUxU2sWDwt-p2cDf8bb8XenU0PZb97XgtKCO_TM-QxMYE=\" rel=\"nofollow\" target=\"_blank\"><u>Publications and Presentations<\/u><\/a> page of the Corvus website.<\/p>\n<p align=\"left\">\n        <strong>About\u00a0Corvus Pharmaceuticals<\/strong><br \/>\n        <br \/>Corvus Pharmaceuticals\u00a0is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company\u2019s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jGU5uiSi7xs_UeioG5N15qzh_vr17VxiRjO793fGSzB5cfgGr8s4Q6QPDzd64zR1lvYTjrJKsP87UW5fb7fn815lvbC20gmfm3qb-8OfgwZL_0NojMoqNRuGk7Ef1UYQgh_dR-Dr55CKwIN4ehgjmf3hQyUXMjqlfwRYa1_6y8N9oL9znJVFepY7qJQSttr4jDyp73IXurw0Z1JnZDKIVuwp2e49RKq7-9T0_pvKYeSnMcR1FwQU5ACeSQM-7bn_X-EMFYx7kGmF0xkkzQiEnQ==\" rel=\"nofollow\" target=\"_blank\"><u>www.corvuspharma.com<\/u><\/a>.<\/p>\n<p align=\"left\">\n        <strong>INVESTOR CONTACT:<\/strong><br \/>\n        <br \/>Leiv Lea<br \/>Chief Financial Officer<br \/>Corvus Pharmaceuticals, Inc.<br \/>+1-650-900-4522<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-xkC731-ZhLEv_L4YdTyy_iJ5pxSBUTzOr5PmMDmdm_hEN8fnd72fvHLe8usI7X5FxEN3P0SO0Oy77AKPX_sdDnxLQLxzr9Ja8V8qSDvUKU=\" rel=\"nofollow\" target=\"_blank\"><u>llea@corvuspharma.com<\/u><\/a><\/p>\n<p align=\"left\">\n        <strong>MEDIA CONTACT:<\/strong><br \/>\n        <br \/>Sheryl Seapy<br \/>Real Chemistry<br \/>+1-949-903-4750<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jtclOj0cNIf0i-sz4e9SBnLO2dbiVMS2TiQORewf7-IGBfM7VHvBF13wCtI2YSj_rWmyMQntKLuXxTvTOEH_n3o72rV1-Ed0w31j4sLhJrg=\" rel=\"nofollow\" target=\"_blank\"><u>sseapy@realchemistry.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMDc4MyM2NjQwMzM4IzIwMjU5OTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MDRlZGJiZGEtMzAzMC00MDUxLWJlZWItMzU1MzBlY2UwZGEzLTEwMzc1NjU=\/tiny\/Corvus-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Company to host conference call and webcast at 8:00 a.m. ET \/ 5:00 a.m. PT on Wednesday, December 18, 2024 BURLINGAME, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) &#8212; Corvus Pharmaceuticals, Inc.\u00a0(NASDAQ: CRVS), a clinical-stage biopharmaceutical company, will announce interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis tomorrow, December 18, 2024. The data will be provided in a press release and presented during a conference call and webcast. Conference Call, Webcast and Presentation Slides Corvus will host a conference call and webcast tomorrow, Wednesday, December 18, 2024 at 8:00 a.m. ET \/ 5:00 a.m. PT to provide an overview of the soquelitinib atopic dermatitis Phase 1 clinical data. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-795569","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Company to host conference call and webcast at 8:00 a.m. ET \/ 5:00 a.m. PT on Wednesday, December 18, 2024 BURLINGAME, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) &#8212; Corvus Pharmaceuticals, Inc.\u00a0(NASDAQ: CRVS), a clinical-stage biopharmaceutical company, will announce interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis tomorrow, December 18, 2024. The data will be provided in a press release and presented during a conference call and webcast. Conference Call, Webcast and Presentation Slides Corvus will host a conference call and webcast tomorrow, Wednesday, December 18, 2024 at 8:00 a.m. ET \/ 5:00 a.m. PT to provide an overview of the soquelitinib atopic dermatitis Phase 1 clinical data. &hellip; Continue reading &quot;Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-17T21:04:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMDc4MyM2NjQwMzM4IzIwMjU5OTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024\",\"datePublished\":\"2024-12-17T21:04:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\\\/\"},\"wordCount\":576,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMDc4MyM2NjQwMzM4IzIwMjU5OTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\\\/\",\"name\":\"Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMDc4MyM2NjQwMzM4IzIwMjU5OTM=\",\"datePublished\":\"2024-12-17T21:04:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMDc4MyM2NjQwMzM4IzIwMjU5OTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTMyMDc4MyM2NjQwMzM4IzIwMjU5OTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\/","og_locale":"en_US","og_type":"article","og_title":"Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024 - Market Newsdesk","og_description":"Company to host conference call and webcast at 8:00 a.m. ET \/ 5:00 a.m. PT on Wednesday, December 18, 2024 BURLINGAME, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) &#8212; Corvus Pharmaceuticals, Inc.\u00a0(NASDAQ: CRVS), a clinical-stage biopharmaceutical company, will announce interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis tomorrow, December 18, 2024. The data will be provided in a press release and presented during a conference call and webcast. Conference Call, Webcast and Presentation Slides Corvus will host a conference call and webcast tomorrow, Wednesday, December 18, 2024 at 8:00 a.m. ET \/ 5:00 a.m. PT to provide an overview of the soquelitinib atopic dermatitis Phase 1 clinical data. &hellip; Continue reading \"Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\/","og_site_name":"Market Newsdesk","article_published_time":"2024-12-17T21:04:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMDc4MyM2NjQwMzM4IzIwMjU5OTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024","datePublished":"2024-12-17T21:04:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\/"},"wordCount":576,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMDc4MyM2NjQwMzM4IzIwMjU5OTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\/","name":"Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMDc4MyM2NjQwMzM4IzIwMjU5OTM=","datePublished":"2024-12-17T21:04:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMDc4MyM2NjQwMzM4IzIwMjU5OTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTMyMDc4MyM2NjQwMzM4IzIwMjU5OTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/corvus-pharmaceuticals-to-announce-interim-data-from-placebo-controlled-phase-1-clinical-trial-of-soquelitinib-for-atopic-dermatitis-on-december-18-2024\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/795569","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=795569"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/795569\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=795569"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=795569"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=795569"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}